Amitiza
Amitiza Brand names, Amitiza Analogs
Amitiza Brand Names Mixture
- No information avaliable
Amitiza Chemical_Formula
C21H16ClF3N4O3
Amitiza RX_link
No information avaliable
Amitiza fda sheet
Amitiza msds (material safety sheet)
Amitiza Synthesis Reference
No information avaliable
Amitiza Molecular Weight
464.825 g/mol
Amitiza Melting Point
No information avaliable
Amitiza H2O Solubility
Practically insoluble (as tosylate salt)
Amitiza State
Solid
Amitiza LogP
3.671
Amitiza Dosage Forms
Tablets (oral, 200 mg)
Amitiza Indication
For the treatment of patients with advanced renal cell carcinoma.
Amitiza Pharmacology
Sorafenib is a multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinases. It is commonly available as a tosylate salt. Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib inhibits tumor growth of the murine renal cell carcinoma, RENCA, and several other human tumor xenografts in athymic mice. A reduction in tumor angiogenesis occurs in some tumor xenograft models.
Amitiza Absorption
The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.
Amitiza side effects and Toxicity
The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.
Amitiza Patient Information
Amitiza Organisms Affected
Humans and other mammals
